LPCN (Lipocine Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by LPCN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Michael Grissinger | Director | A | — | — |
| 2026-08-07 | Michael Grissinger | Director | A | — | — |
| 2026-06-04 | Richard Dana Ono | Director | A | — | — |
| 2026-06-04 | John W. Higuchi | Director | A | — | — |
| 2026-06-04 | Jill M. Jene | Director | A | — | — |
| 2026-04-07 | John W. Higuchi | Director | Buy | — | — |
| 2026-04-06 | John W. Higuchi | Director | Buy | — | — |
| 2026-04-06 | Mahesh V. Patel | Chief Executive Officer | Buy | — | — |
| 2026-04-02 | Mahesh V. Patel | Chief Executive Officer | Buy | — | — |
| 2026-01-05 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2025-12-19 | Krista Fogarty | Principal Accounting Officer | A | — | — |
| 2025-12-19 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2025-06-05 | Richard Dana Ono | Director | A | — | — |
| 2025-06-05 | Jill M. Jene | Director | A | — | — |
| 2025-06-05 | Spyros Papapetropoulos | Director | A | — | — |
| 2025-06-05 | Jeffrey Arvin Fink | Director | A | — | — |
| 2025-06-05 | John W. Higuchi | Director | A | — | — |
| 2025-01-02 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2025-01-02 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2024-12-30 | Krista Fogarty | Principal Accounting Officer | A | — | — |
| 2024-12-30 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2024-06-07 | Jeffrey Arvin Fink | Director | A | — | — |
| 2024-06-07 | Spyros Papapetropoulos | Director | A | — | — |
| 2024-06-07 | Jill M. Jene | Director | A | — | — |
| 2024-06-07 | John W. Higuchi | Director | A | — | — |
| 2024-06-07 | Richard Dana Ono | Director | A | — | — |
| 2024-03-12 | Krista Fogarty | Principal Accounting Officer | A | — | — |
| 2024-03-12 | Mahesh V. Patel | CEO and President | A | — | — |
| 2023-05-25 | Mahesh V. Patel | CEO and President | Buy | — | — |
| 2023-05-12 | Jill M. Jene | Director | A | — | — |
| 2023-05-12 | Jeffrey Arvin Fink | Director | A | — | — |
| 2023-05-12 | Spyros Papapetropoulos | Director | A | — | — |
| 2023-05-12 | Richard Dana Ono | Director | A | — | — |
| 2023-05-12 | John W. Higuchi | Director | A | — | — |
| 2023-03-24 | Mahesh V. Patel | CEO and President | Buy | — | — |
| 2023-03-20 | Richard Dana Ono | Director | Buy | — | — |
| 2023-03-17 | Mahesh V. Patel | CEO and President | Buy | — | — |
| 2023-01-04 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2022-12-22 | Krista Fogarty | Principal Accounting Officer | A | — | — |
| 2022-12-22 | Mahesh V. Patel | Chief Executive Officer | A | — | — |
| 2022-11-28 | Spyros Papapetropoulos | Director | Buy | — | — |
| 2022-11-14 | Mahesh V. Patel | CEO and President | Buy | — | — |
| 2022-11-08 | George Nomikos | Chief Medical Officer | A | — | — |
| 2022-09-27 | Mahesh V. Patel | CEO and President | Buy | — | — |
| 2022-06-10 | Jill M. Jene | Director | A | — | — |
| 2022-06-10 | John W. Higuchi | Director | A | — | — |
| 2022-06-10 | Spyros Papapetropoulos | Director | A | — | — |
| 2022-06-10 | Jeffrey Arvin Fink | Director | A | — | — |
| 2022-06-10 | Richard Dana Ono | Director | A | — | — |
| 2022-05-17 | Krista Fogarty | Principal Accounting Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 203,797 | — |
| — | Chief Executive Officer | 160,679 | — |
| — | Chief Financial Officer | 11,441 | — |
| — | Principal Accounting Officer | 1,727 | — |
| — | Director | 1,279 | — |
| — | Director | 831 | — |
| — | Director | 750 | — |
| — | Chief Commercial Officer | 551 | — |
| — | Director | 386 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LPCN quote page; the site-wide leaderboard is on the insider transactions hub.